vs
Side-by-side financial comparison of IMAX CORP (IMAX) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.
IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $69.8M, roughly 1.8× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 0.5%, a 383.5% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 21.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 25.8%).
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.
IMAX vs RIGL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $125.2M | $69.8M |
| Net Profit | $637.0K | $268.1M |
| Gross Margin | 57.6% | 91.5% |
| Operating Margin | 19.3% | 33.2% |
| Net Margin | 0.5% | 384.0% |
| Revenue YoY | 35.1% | 21.2% |
| Net Profit YoY | -88.0% | 1769.2% |
| EPS (diluted) | $0.02 | $14.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $125.2M | $69.8M | ||
| Q3 25 | $106.7M | $69.5M | ||
| Q2 25 | $91.7M | $101.7M | ||
| Q1 25 | $86.7M | $53.3M | ||
| Q4 24 | $92.7M | $57.6M | ||
| Q3 24 | $91.5M | $55.3M | ||
| Q2 24 | $89.0M | $36.8M | ||
| Q1 24 | $79.1M | $29.5M |
| Q4 25 | $637.0K | $268.1M | ||
| Q3 25 | $20.7M | $27.9M | ||
| Q2 25 | $11.3M | $59.6M | ||
| Q1 25 | $2.3M | $11.4M | ||
| Q4 24 | $5.3M | $14.3M | ||
| Q3 24 | $13.9M | $12.4M | ||
| Q2 24 | $3.6M | $-1.0M | ||
| Q1 24 | $3.3M | $-8.2M |
| Q4 25 | 57.6% | 91.5% | ||
| Q3 25 | 63.1% | 93.2% | ||
| Q2 25 | 58.5% | 95.6% | ||
| Q1 25 | 61.4% | 91.7% | ||
| Q4 24 | 52.2% | 89.9% | ||
| Q3 24 | 55.8% | 85.5% | ||
| Q2 24 | 49.4% | 92.4% | ||
| Q1 24 | 59.3% | 93.1% |
| Q4 25 | 19.3% | 33.2% | ||
| Q3 25 | 27.2% | 40.9% | ||
| Q2 25 | 15.6% | 60.1% | ||
| Q1 25 | 19.3% | 23.9% | ||
| Q4 24 | 10.3% | 28.9% | ||
| Q3 24 | 21.2% | 25.4% | ||
| Q2 24 | 3.2% | 1.2% | ||
| Q1 24 | 15.3% | -23.6% |
| Q4 25 | 0.5% | 384.0% | ||
| Q3 25 | 19.4% | 40.2% | ||
| Q2 25 | 12.3% | 58.6% | ||
| Q1 25 | 2.7% | 21.5% | ||
| Q4 24 | 5.7% | 24.9% | ||
| Q3 24 | 15.2% | 22.5% | ||
| Q2 24 | 4.0% | -2.8% | ||
| Q1 24 | 4.1% | -27.9% |
| Q4 25 | $0.02 | $14.11 | ||
| Q3 25 | $0.37 | $1.46 | ||
| Q2 25 | $0.20 | $3.28 | ||
| Q1 25 | $0.04 | $0.63 | ||
| Q4 24 | $0.09 | $0.82 | ||
| Q3 24 | $0.26 | $0.70 | ||
| Q2 24 | $0.07 | $-0.06 | ||
| Q1 24 | $0.06 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $151.2M | $155.0M |
| Total DebtLower is stronger | — | $52.5M |
| Stockholders' EquityBook value | $337.9M | $391.5M |
| Total Assets | $894.0M | $513.6M |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $151.2M | $155.0M | ||
| Q3 25 | $143.1M | $137.1M | ||
| Q2 25 | $109.3M | $108.4M | ||
| Q1 25 | $97.1M | $77.1M | ||
| Q4 24 | $100.6M | $77.3M | ||
| Q3 24 | $104.5M | $61.1M | ||
| Q2 24 | $91.6M | $49.1M | ||
| Q1 24 | $81.0M | $49.5M |
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
| Q4 25 | $337.9M | $391.5M | ||
| Q3 25 | $349.5M | $117.6M | ||
| Q2 25 | $320.4M | $81.9M | ||
| Q1 25 | $299.5M | $18.6M | ||
| Q4 24 | $299.5M | $3.3M | ||
| Q3 24 | $289.4M | $-14.6M | ||
| Q2 24 | $267.2M | $-29.9M | ||
| Q1 24 | $258.8M | $-31.7M |
| Q4 25 | $894.0M | $513.6M | ||
| Q3 25 | $889.6M | $242.5M | ||
| Q2 25 | $868.6M | $206.7M | ||
| Q1 25 | $848.3M | $176.0M | ||
| Q4 24 | $830.4M | $164.0M | ||
| Q3 24 | $847.6M | $139.4M | ||
| Q2 24 | $827.4M | $128.4M | ||
| Q1 24 | $824.1M | $126.5M |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $29.4M | $22.0M |
| Free Cash FlowOCF − Capex | $28.0M | — |
| FCF MarginFCF / Revenue | 22.3% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | 46.11× | 0.08× |
| TTM Free Cash FlowTrailing 4 quarters | $118.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.4M | $22.0M | ||
| Q3 25 | $67.5M | $24.0M | ||
| Q2 25 | $23.2M | $30.5M | ||
| Q1 25 | $7.0M | $-893.0K | ||
| Q4 24 | $11.5M | $14.5M | ||
| Q3 24 | $35.3M | $21.7M | ||
| Q2 24 | $35.0M | $302.0K | ||
| Q1 24 | $-11.0M | $-5.0M |
| Q4 25 | $28.0M | — | ||
| Q3 25 | $64.8M | — | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $5.3M | — | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $34.2M | — | ||
| Q2 24 | $33.5M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 22.3% | — | ||
| Q3 25 | 60.7% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.6% | — | ||
| Q1 24 | -15.3% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 46.11× | 0.08× | ||
| Q3 25 | 3.27× | 0.86× | ||
| Q2 25 | 2.06× | 0.51× | ||
| Q1 25 | 2.99× | -0.08× | ||
| Q4 24 | 2.16× | 1.01× | ||
| Q3 24 | 2.54× | 1.75× | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
RIGL
Segment breakdown not available.
